H.C. Wainwright analyst Robert Burns raised the firm’s price target on MacroGenics to $14 from $12 and keeps a Buy rating on the shares. The analyst finds lorigerlimab’s early Phase 1 castration-resistant prostate cancer data "encouraging."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MGNX:
- MacroGenics downgraded to Neutral at Guggenheim on prostate cancer caution
- MacroGenics downgraded to Neutral from Buy at Guggenheim
- MacroGenics Provides Corporate Update and 2022 Financial Results
- MacroGenics expands license agreement with Synaffix
- MacroGenics informs investors of no exposure to Silicon Valley Bank